Barr C
International Pharmaceuticals Group, Pfizer Inc, New York, USA.
Pharmacoeconomics. 1994;6 Suppl 1:61-2. doi: 10.2165/00019053-199400061-00014.
As a responsible partner in healthcare systems, the pharmaceutical industry hopes to see a research agenda on pharmaceutical issues that will provide more information on trends in healthcare reform affecting medicines. Urgent questions include whether some forms of cost containment are harming innovation and the quality of care, and what constructive alternatives to policies such as reference pricing can the industry offer?
作为医疗保健系统中负责任的合作伙伴，制药行业希望看到一份关于制药问题的研究议程，该议程将提供更多有关影响药品的医疗改革趋势的信息。紧迫的问题包括某些形式的成本控制是否正在损害创新和医疗质量，以及制药行业能为参考定价等政策提供哪些建设性的替代方案？
